Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDURA vs ANDROID 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective antagonist of alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and prostate.
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Hypertension,Benign prostatic hyperplasia
Hypogonadism in males (primary and secondary),Delayed puberty in males,Metastatic breast cancer in women (as palliative therapy)
Initial: 1 mg orally once daily, titrated based on standing blood pressure response up to 16 mg daily as a single dose or divided twice daily. Maximum: 16 mg/day.
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
Terminal elimination half-life is approximately 22 hours, allowing once-daily dosing; peak effect on blood pressure occurs at 2-6 hours post-dose.
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Extensively metabolized in the liver via O-demethylation and hydroxylation; CYP3A4 is the major enzyme involved.
Primarily hepatic via reduction and oxidation; metabolites include androsterone and etiocholanolone; excreted in urine.
Primarily hepatic metabolism (approx. 60-70%) with biliary excretion of metabolites; renal excretion accounts for about 30-40% of the dose, mainly as metabolites with <5% unchanged drug.
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
98-99% bound to plasma proteins (primarily albumin).
97–99% (sex hormone-binding globulin and albumin)
0.5-1.0 L/kg (approximately 50-70 L in adults); indicates extensive extravascular distribution.
0.3–0.6 L/kg; indicates distribution into lean muscle and sex organs
Oral bioavailability is approximately 65% (range 43-81%) with minimal first-pass effect.
Oral: <5% (methyltestosterone: ~20–25% due to 17α-alkylation); IM: 100%
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, start with 0.5 mg daily and titrate cautiously due to increased sensitivity.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose or increasing interval; monitor for fluid retention and hypertension.
Child-Pugh A: Start at 0.5 mg daily. Child-Pugh B or C: Contraindicated due to extensive hepatic metabolism.
Contraindicated in Child-Pugh class B or C cirrhosis. For mild hepatic impairment (Child-Pugh A), start with lower dose (e.g., 12.5 mg every 2 weeks) and titrate based on response and liver function.
Safety and efficacy not established in pediatric patients; use not recommended.
Not recommended for use in pediatric patients (safety and efficacy not established). For male adolescents with hypogonadism, individualize: start at 12.5 mg every 2 weeks and adjust based on testosterone levels and growth.
Initiate at 0.5 mg daily due to increased risk of orthostatic hypotension. Titrate slowly based on tolerability and response.
Start with lower initial dose (e.g., 12.5 mg every 2 weeks); monitor prostate-specific antigen (PSA) and hematocrit frequently. Avoid in patients with prostate cancer or untreated sleep apnea.
None
WARNING: Androgens are contraindicated in pregnancy due to masculinization of female fetus. Hepatotoxicity, including peliosis hepatis and hepatic neoplasms, has been reported with prolonged use.
Orthostatic hypotension and syncope, especially with first dose,Use with caution in patients with hepatic impairment,Risk of priapism,Intraoperative floppy iris syndrome during cataract surgery
Use with caution in patients with hepatic, renal, or cardiovascular disease; may cause gynecomastia, edema, hypercalcemia, and polycythemia; monitor liver function, lipid profile, and hematocrit periodically; may accelerate bone maturation in children; risk of prostate hypertrophy and urethral obstruction.
Hypersensitivity to doxazosin or other quinazolines
Known or suspected prostate cancer; male breast cancer; pregnancy; lactation; hypersensitivity to methyltestosterone; severe hepatic impairment.
Avoid grapefruit and grapefruit juice as they may increase doxazosin levels. Take with food to reduce gastrointestinal upset. No other significant food interactions.
Take with food containing fat (e.g., avocado, nuts, olive oil) to enhance absorption. Avoid grapefruit juice as it may increase testosterone levels via CYP3A4 inhibition. Limit alcohol due to potential liver effects.
Pregnancy Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimesters: Potential risk of fetal hypotension and hypoxia from maternal hypotension. Avoid use in pregnancy unless benefit outweighs risk.
Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure occurs before 12 weeks gestation. Second and third trimesters: Continued risk of female pseudohermaphroditism, and potential for masculinization of female external genitalia. Androgens can cross the placenta and may also cause skeletal abnormalities and growth retardation. Pregnancy category X.
Excreted in human milk; M/P ratio unknown. Caution due to potential for hypotension in nursing infants. Use only if essential.
Methyltestosterone is excreted into breast milk; M/P ratio not established. May cause virilization in female infants and premature sexual development in male infants. Androgens can suppress lactation. Use during breastfeeding is contraindicated.
No established dose adjustments for pregnancy; use lowest effective dose due to potential for increased clearance and changes in volume of distribution.
Android 25 is contraindicated in pregnancy, so no dosing adjustments are applicable. If used inadvertently, discontinue immediately. No pharmacokinetic data to guide dose changes; avoid use entirely.
CARDURA (doxazosin) is an alpha-1 blocker used for hypertension and benign prostatic hyperplasia (BPH). First-dose syncope is more common with immediate-release (IR) than extended-release (GITS). Start IR at 1 mg at bedtime and titrate slowly. GITS formulation minimizes orthostatic effects. Monitor blood pressure carefully in elderly patients. May cause intraoperative floppy iris syndrome (IFIS) during cataract surgery; do not stop therapy preoperatively. Avoid use in patients with orthostatic hypotension or micturition syncope.
Android 25 (testosterone undecanoate) requires absorption via lymphatic system; administer with fat-containing meal. Monitor serum testosterone levels 3-5 hours post-dose. Avoid in patients with breast cancer or known or suspected prostate cancer. Risk of polycythemia; check hematocrit before and during therapy.
Take the first dose at bedtime to minimize dizziness. Sit or lie down if you feel lightheaded.,Avoid sudden position changes; rise slowly from sitting or lying positions.,May cause dizziness, drowsiness, or blurred vision. Do not drive until you know how CARDURA affects you.,For BPH, it may take up to 2 weeks to improve symptoms. Do not stop medication abruptly.,Inform your surgeon if you are scheduled for cataract surgery; CARDURA may affect eye surgery outcomes.,Avoid alcohol, which can worsen side effects like dizziness and low blood pressure.,For hypertension, continue regular monitoring with your healthcare provider.
Take capsules with meals, especially those containing fat, to improve absorption.,Do not chew or crush capsules; swallow whole.,Report signs of deep vein thrombosis (leg swelling, pain) or pulmonary embolism (sudden dyspnea, chest pain).,Women of reproductive potential should avoid pregnancy; use effective contraception.,Keep out of reach of children; testosterone can cause serious harm if accidentally ingested.,Regular blood tests (testosterone, hematocrit, PSA, lipid profile) are required.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDURA vs ANDROID 25, answered by our medical review team.
CARDURA is a Alpha-1 Blocker Antihypertensive that works by Selective antagonist of alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and prostate.. ANDROID 25 is a Androgen that works by Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDURA and ANDROID 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDURA is: Initial: 1 mg orally once daily, titrated based on standing blood pressure response up to 16 mg daily as a single dose or divided twice daily. Maximum: 16 mg/day.. The standard adult dose of ANDROID 25 is: Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDURA and ANDROID 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDURA is classified as Category C. Pregnancy Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimesters: Potential risk of fetal hypotension and hypoxia. ANDROID 25 is classified as Category C. Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure oc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.